AMANTA HEALTHCARE IPO

Dhan Kirti is pleased to present a comprehensive overview of the upcoming Initial Public Offering (IPO) of Amanta Healthcare. This detailed analysis aims to provide potential investors with essential information, from the company’s core operations and financial health to the critical timelines and potential risks associated with the offering. Understanding these facets is crucial for making informed investment decisions.

Snapshot of the Offering

Amanta Healthcare, a specialist in sterile liquid pharmaceutical formulations, is set to open its public subscription. Below is a quick glance at the vital details of this highly anticipated IPO.

The IPO is entirely a fresh issue of equity shares, with no offer for sale component, indicating that all proceeds will directly flow into the company to support its growth objectives.

Important Dates for Investors

Investors interested in participating in the Amanta Healthcare IPO should mark these critical dates on their calendars. Adhering to the timeline, especially for application and payment deadlines, is essential.

• Opening Date: 01 Sep 2025
• Closing Date: 03 Sep 2025
• UPI Payment Deadline: 03 Sep 2025 (5:00 PM)
• Allotment Announcement: 04 Sep 2025
• Refund Processing: 08 Sep 2025
• Demat Credit: 08 Sep 2025
• Stock Market Listing: 09 Sep 2025
• Mandate Validity End: 18 Sep 2025
• Anchor Investor Lock-in Release (50%): 04 Oct 2025
• Anchor Investor Lock-in Release (Remaining): 03 Dec 2025

*Dates may be revised as per official updates by the company or regulatory authorities. Investors are advised to refer to the official RHP for the most accurate and updated schedule.

Understanding Amanta Healthcare: A Sector Overview

Founded in 1994, Amanta Healthcare is a distinguished pharmaceutical formulation manufacturer, deeply entrenched in the specialty of sterile liquid formulations. The company’s operations span across multiple critical therapeutic segments, including fluid therapy, respiratory care, ophthalmic solutions, diluents, and irrigation solutions. This diversified portfolio allows Amanta Healthcare to cater to a broad spectrum of medical needs within the healthcare ecosystem.

The company’s robust manufacturing backbone is centered at its state-of-the-art facility in Hariyala, Kheda district, Gujarat. Spanning over 66,000 square meters, this facility is equipped with advanced Large Volume Parenteral (LVP) and Small Volume Parenteral (SVP) lines. It leverages cutting-edge technologies such as Aseptic Blow Fill Seal (ABFS) and Injection Stretch Blow Moulding (ISBM), which are pivotal for producing high-quality, sterile liquid products. These technologies ensure the integrity and safety of formulations, which is paramount in the pharmaceutical industry.

Amanta Healthcare is committed to global quality standards, evidenced by its array of prestigious certifications. It is WHO-GMP compliant, signifying adherence to international manufacturing practices, and holds ISO 9001:2015 for quality management, ISO 13485:2016 for medical devices quality management, ISO 14001:2015 for environmental management, and ISO 45001:2018 for occupational health and safety management. These certifications underscore the company’s dedication to quality, safety, and operational excellence, positioning it as a reliable player in the highly regulated pharmaceutical sector.

Issue Structure and Capital Mobilization

The Amanta Healthcare IPO is designed to raise capital entirely through a fresh issue of shares, signaling the company’s intent to channel all proceeds directly into business expansion and operational enhancement. This structure is often viewed favorably by investors as it suggests a direct reinvestment into the company’s growth trajectory.

The absence of an Offer for Sale (OFS) component means that no existing shareholders are selling their stake, and thus, all the funds raised will be utilized by Amanta Healthcare itself. This focus on internal capital generation is a positive indicator for long-term growth prospects.

Deployment of Fresh Issue Proceeds

Amanta Healthcare has clearly outlined the strategic allocation of the capital raised through this IPO. The funds are primarily earmarked for significant capital expenditures aimed at expanding its manufacturing capabilities, which are crucial for meeting growing market demand and enhancing its product portfolio.

The largest portion of the funds, over 55%, is dedicated to establishing a new manufacturing line for its SteriPort products, indicating a strategic focus on expanding this particular segment. A substantial 24% is allocated to a new SVP manufacturing line, further enhancing its sterile liquid capabilities. The remaining 20.5% is designated for general corporate purposes, providing flexibility for operational needs, working capital, and other strategic initiatives that may arise as the company grows.

Distinctive Advantages of Amanta Healthcare

Amanta Healthcare has built a strong foundation and market presence by leveraging several key strengths that differentiate it in the competitive pharmaceutical landscape:

• Long-Standing Heritage and Diversified Portfolio: Established in 1994, the company boasts a rich history in the pharmaceutical sector, coupled with a diversified product portfolio of sterile liquid formulations that caters to multiple therapeutic areas. This broad offering helps mitigate risks associated with reliance on a single product line.
• Advanced Sterile Liquid Manufacturing: The company possesses state-of-the-art capabilities in advanced sterile liquid manufacturing, covering a wide volume range from SVPs to LVPs. This technical proficiency is critical for producing high-quality, specialized products that require stringent manufacturing environments.
• Globally Certified Manufacturing Facility: Amanta Healthcare operates a manufacturing facility that is not only WHO-GMP compliant but also holds multiple ISO certifications (9001:2015, 13485:2016, 14001:2015, and 45001:2018). These certifications reflect a commitment to international quality, environmental, and safety standards, enhancing trust among clients and regulators.
• Extensive Distribution and Sales Network: The company benefits from a well-established and extensive domestic as well as global distribution and sales network. This wide reach enables efficient product delivery and market penetration, ensuring products reach a broad customer base.
• Experienced Leadership and Skilled Workforce: Amanta Healthcare is led by an experienced management team and supported by a skilled and qualified employee base. This human capital expertise is crucial for driving innovation, maintaining operational excellence, and navigating the complexities of the pharmaceutical industry.

Assessing Investment Risks

While Amanta Healthcare presents several strengths, potential investors should also be aware of the inherent risks associated with the company and the industry:

• High Customer Concentration: A significant portion of the company’s revenue might be derived from a limited number of customers. This high customer concentration could pose risks to revenue stability and create dependency, making the company vulnerable to changes in demand or relationships with these key clients.
• Delay in Expansion Plans: The growth trajectory of Amanta Healthcare is significantly tied to its planned expansion, particularly the new manufacturing lines for SteriPort and SVP. Any delays in setting up or commissioning these facilities could directly impact the company’s projected growth, production capacity, and profitability.
• Promoter Guarantees on Loans: The company’s promoters have provided personal guarantees tied to certain loans. While common, this arrangement can affect operational flexibility if financial covenants are breached or if the company faces financial distress, potentially leading to increased scrutiny or constraints.
• Product Liability Exposure: Given that Amanta Healthcare specializes in sterile liquid pharmaceutical products, it faces significant product liability exposure. Any quality issues, contamination, or adverse reactions related to its products could lead to lawsuits, regulatory penalties, reputational damage, and substantial financial losses.
• Unsecured Borrowings and Personal Guarantees: A reliance on unsecured borrowings and personal guarantees from promoters increases the company’s financial vulnerability. In challenging economic conditions or during periods of financial strain, these arrangements could pose liquidity risks and impact the company’s ability to secure further financing on favorable terms.

Tracking Investor Participation

Monitoring the subscription data provides valuable insights into investor sentiment and demand for the IPO. The figures below reflect the investor participation across various categories for Amanta Healthcare IPO as of the closing date.

*The subscription data indicates robust demand across all investor categories, particularly from Non-Institutional Investors. While unofficial Grey Market Premium (GMP) figures may circulate, exchange data on subscription levels is generally considered a more reliable indicator of investor interest and potential listing performance.

Seamless Application Process

Prospective investors who wish to participate in the Amanta Healthcare IPO can do so conveniently through the official Dhan Kirti IPO platform. Ensure your application is submitted before the subscription window closes on September 03, 2025.

Investors can participate in this IPO via the official Dhan Kirti IPO platform before the subscription closes.